Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  CEL-SCI Corporation       US1508374097

CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
More about the company
Financials ($)
Sales 2015 0,47 M
EBIT 2015 -37,6 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
Sales 2016 0,79 M
EBIT 2016 -36,5 M
Net income 2016 -
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 211x
Capi. / Sales 2016 125x
Capitalization 98,9 M
More Financials
10:17a CEL SCI : NEW STORY CEL-SCI Reports 2nd Consecutive Month of Record Patient Enro..
10:17a CEL SCI : NEW STORY CEL-SCI Completes Key Milestone with Clearance to Conduct Ph..
08:16a CEL SCI : Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for..
02:16aDJBritish American Tobacco PLC BAT submits notice of proposed offer for SouzaCr..
03/02 CEL SCI : gets clearance to conduct Phase III trial of cancer drug Multikine in ..
02/27 CEL SCI : NEW STORY CEL-SCI to Participate in Ascendiant's Quarterly Management ..
02/27 CEL SCI : Completes Key Milestone with Clearance to Conduct Phase III Trial in 2..
02/27 CEL-SCI CORPORATION : (NYSE MKT: CVM), Arguably the Most Undervalued Phase III B..
More news
Sector news Bio Therapeutic Drugs
10:51a MEDIVATION : Tuesday 3/3 Insider Buying Report: MDVN, QSR
03/02 PUMA BIOTECHNOLOGY : Biotech reports 4Q loss
03/02 PUMA BIOTECHNOLOGY : Reports Fourth Quarter and Full Year 2014 Financial Results
Plus d'actualités du secteur Bio Therapeutic Drugs
Income Statement Evolution
More Financials
Dynamic quotes